Table 1.
Clinicopathologic and treatment characteristics of patients in the translational cohort versus remaining NSABP B-42 patients.
| Characteristics | Translational B-42 cohort N = 2,178 (%) | Remaining B-42 patients N = 1,725 (%) | P valuea |
|---|---|---|---|
| Age at randomization | 0.05 | ||
| <55 years | 320 (14.7) | 284 (16.5) | |
| 55–65 years | 984 (45.2) | 801 (46.4) | |
| 66–75 years | 662 (30.4) | 510 (29.6) | |
| >75 years | 212 (9.7) | 130 (7.5) | |
| Nodal status | <0.01 | ||
| Negative | 1,307 (60.0) | 933 (54.1) | |
| Positive | 871 (40.0) | 792 (45.9) | |
| Lowest BMD T-score | 1.00 | ||
| ≤−2.0 | 532 (24.4) | 422 (24.5) | |
| >−2.0 | 1,646 (75.6) | 1,303 (75.5) | |
| Prior tamoxifen | 0.32 | ||
| No | 1,342 (61.6) | 1,035 (60.0) | |
| Yes | 836 (38.4) | 690 (40.0) | |
| HER2 status | 0.01 | ||
| Positive | 297 (13.6) | 262 (15.2) | |
| Negative | 1,732 (79.5) | 1,309 (75.9) | |
| Unknown | 149 (6.8) | 154 (8.9) | |
| Surgery type | 0.36 | ||
| Lumpectomy | 1,339 (61.5) | 1,035 (60.0) | |
| Mastectomy | 839 (38.5) | 690 (40.0) | |
| Treatment | 1.00 | ||
| Placebo | 1,090 (50.0) | 863 (50.0) | |
| Letrozole | 1,088 (50.0) | 862 (50.0) |
Abbreviation: BMD, bone mineral density.
a P values comparing the translational cohort versus the remaining B-42 patients were calculated using Chi-square test.